PHARVARIS NV

Pharvaris NV insiders trade a mixed‑bag deal on May 15, 2026—Glassman buys at $22.31 and sells at $29.82‑$29.83, signaling bullish confidence amid rising stock.

Pharvaris insider sale: CMO Lu Peng’s routine liquidity move shows long‑term confidence amid a 120% rally and Phase‑3 data anticipation.

Pharvaris insider sales show routine 10b5‑1 divestitures, no sharp price impact—focus remains on strong quarterly results and future clinical milestones.

Pharvaris insider trades reveal executives buying at €2.59 and selling around €30, showing confidence in the company’s rare‑disease pipeline and future milestones.

Pharvaris NV insider selling: CEO’s modest 23,333‑share sale amid a 10% rally signals routine portfolio management, not a bearish warning. Learn how this move reflects executive confidence and impacts investor strategy.

Pharvaris insider selling signals a strategic re‑balance, offering investors early insight into the company’s pipeline confidence and portfolio strategy.

Pharvaris insider sale: Nijdam Anna sells 1,164 shares amid upcoming Phase 3 results—signals routine portfolio balance, not a bearish warning.

Pharvaris NV insider Abele Stefan Andreas adjusts holdings, boosting investor confidence amid active social‑media buzz and strong Phase 3 clinical progress.

Pharvaris insider Souverijns keeps 55k shares, showing strong confidence in its B2 antagonist pipeline and a long‑term growth outlook.